Literature DB >> 10933117

Treatment of childhood-onset schizophrenia with olanzapine.

E H Sholevar1, D A Baron, T L Hardie.   

Abstract

This paper reports on a clinical observation of 15 hospitalized youths ages 6-13 years diagnosed with childhood-onset schizophrenia and acutely treated with olanzapine. Initial sedation was the most common side effect observed. Youngsters who had not had a previous trial on any psychotropic did better than those that had failed a previous medication trial. Age was inversely correlated with positive response to olanzapine. Patients who experienced initial sedation did best once the initial sedation wore off. The majority of patients in the study improved on olanzapine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10933117     DOI: 10.1089/cap.2000.10.69

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  11 in total

Review 1.  The safety of olanzapine in young children: a systematic review and meta-analysis.

Authors:  Jacqueline Flank; Lillian Sung; Christopher C Dvorak; Wendy Spettigue; L Lee Dupuis
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

Review 2.  Children with schizophrenia: clinical picture and pharmacological treatment.

Authors:  Gabriele Masi; Maria Mucci; Cinzia Pari
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

3.  Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.

Authors:  C Fleischhaker; P Heiser; K Hennighausen; B Herpertz-Dahlmann; K Holtkamp; C Mehler-Wex; R Rauh; H Remschmidt; E Schulz; A Warnke
Journal:  J Neural Transm (Vienna)       Date:  2006-11-17       Impact factor: 3.575

Review 4.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders.

Authors:  Vivek Agarwal; Prabhat Sitholey
Journal:  Indian J Psychiatry       Date:  2006-01       Impact factor: 1.759

6.  Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.

Authors:  Ann E Maloney; Linmarie Sikich
Journal:  Neuropsychiatr Dis Treat       Date:  2010-11-10       Impact factor: 2.570

Review 7.  Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.

Authors:  José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-17       Impact factor: 4.785

Review 8.  Antipsychotics in early onset Schizophrenia: Systematic review and meta-analysis.

Authors:  Jorge L Armenteros; Mark Davies
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-02-09       Impact factor: 4.785

9.  Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.

Authors:  Christian Fleischhaker; Philip Heiser; Klaus Hennighausen; Beate Herpertz-Dahlmann; Kristian Holtkamp; Claudia Mehler-Wex; Reinhold Rauh; Helmut Remschmidt; Eberhard Schulz; Andreas Warnke
Journal:  J Neural Transm (Vienna)       Date:  2008-09-09       Impact factor: 3.575

10.  Psychosis in children: diagnosis and treatment.

Authors:  H Courvoisie; M J Labellarte; M A Riddle
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.